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Abstract
An increasing number of genetic variants have been identified for many complex diseases. However, it is controversial
whether risk prediction based on genomic profiles will be useful clinically. Appropriate statistical measures to evaluate the
performance of genetic risk prediction models are required. Previous studies have mainly focused on the use of the area
under the receiver operating characteristic (ROC) curve, or AUC, to judge the predictive value of genetic tests. However,
AUC has its limitations and should be complemented by other measures. In this study, we develop a novel unifying
statistical framework that connects a large variety of predictive indices together. We showed that, given the overall disease
probability and the level of variance in total liability (or heritability) explained by the genetic variants, we can estimate
analytically a large variety of prediction metrics, for example the AUC, the mean risk difference between cases and non-
cases, the net reclassification improvement (ability to reclassify people into high- and low-risk categories), the proportion of
cases explained by a specific percentile of population at the highest risk, the variance of predicted risks, and the risk at any
percentile. We also demonstrate how to construct graphs to visualize the performance of risk models, such as the ROC
curve, the density of risks, and the predictiveness curve (disease risk plotted against risk percentile). The results from
simulations match very well with our theoretical estimates. Finally we apply the methodology to nine complex diseases,
evaluating the predictive power of genetic tests based on known susceptibility variants for each trait.
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Introduction
Genome-wide association studies have succeeded in uncovering
many common genetic variants underlying complex diseases,
raising hope for individualized risk prediction based on genomic
profiles. Although the effect size of a single genetic marker is
typically very modest and unlikely to be useful in risk prediction,
prediction based on a collection of susceptibility variants may be
promising. Several commercial companies (such as deCODEme,
Navigenics, 23andMe) are already offering disease risk estimates
based on genomic profiles of susceptibility variants. However, it
remains controversial whether such tests will be useful clinically.
This calls for appropriate measures to evaluate the performance of
genetic risk prediction models. It should be noted that a high level
of statistical significance does not equate to good predictive power
[1,2].
A very popular method of assessing the discriminatory ability of
test is the AUC (also known as the c statistic). AUC can be defined
as the area under the receiver operating curve, which is a plot of
sensitivity versus 1-specificity. AUC is also equal to the probability
that the test score or predicted probability is higher for a case than
a non-case. A few previous studies have investigated the use and
performance of AUC in genetic tests. Janssens et al. [3] performed
a simulation study for the AUC achieved under different
combinations of risk allele frequencies, odds ratios and disease
prevalence. Lu and Elston [4] proposed an approach to construct
the optimal ROC curve based on likelihood ratios. It has also been
observed that the increase in AUC by SNPs to existing risk factors
is in general modest [5].
Despite its widespread use, the ROC curve and AUC are not
without limitations and they are not the only ways to assess the
performance of a prediction model. For instance, it has been
pointed out that that the AUC is not directly related to the
absolute disease risks (i.e. probability of disease given test result),
which is often of great clinical interest [6,7]. Very large OR are
often required to increase the AUC beyond existing risk factors
[8]. In view of these limitations, other indices have been
developed. These included the net reclassification improvement
(NRI) and the integrated discrimination improvement [9]. The
former is concerned with reclassification of subjects into risk
categories and the latter with the mean risk difference in cases and
non-cases. Graphs that display the risk distribution in the
population have been advocated, for example the ‘‘predictiveness
curve’’ [7].
In this study, we propose a novel unifying statistical framework
that connects different measures of predictive power together. The
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framework is based on the liability threshold model, which
assumes an underlying liability that is normally distributed.
Affected individuals have a liability above the threshold. We show
that given the overall disease prevalence and total variance in
liability explained (equivalent to heritability explained) by the set
of susceptibility variants, it is possible to estimate analytically the
aforementioned prediction indices and construct graphs to
visualize the performance of risk models.
Methods
Here we establish links to various measures of predictive power
within our variance explained framework. We will derive analytic
expressions to evaluate different prediction indices.
The liability threshold model
Our statistical framework is based on the liability threshold
model. The methods to derive total variance in liability explained
(Vm) by known variants (or other risk factors) and the
corresponding liability score for each genotype will be presented
elsewhere (So et al., submitted [10]). It is useful to note this Vm can
be interpreted as the total heritability attributed to the known
variants. We partition the total liability into two components, one
comprising known risk factors (i.e. ‘‘measurable’’ liability) and the
other comprising other risk factors yet to be found. The
measurable liability is normally distributed with mean 0 and
variance equal to the total variance (or heritability) explained by
the known variants (s2). The overall liability conditioned on the
measurable liability (z) is normally distributed with mean z and
variance 12s2. Vm and s
2 are used interchangeably in this paper,
with the former usually referring to the concept of variance
explained and the latter referring to its level.
ROC curve and AUC
Consider a 262 table with disease status and test result (Table 1).
Test is defined as positive if the level of measurable liability
exceeds certain percentile cut-off, c. The absolute disease risk (R) is
given by the chance that the overall liability, conditioned on the
measurable liability, exceeds the threshold. R can be expressed as
1{W
T{zffiffiffiffiffiffiffiffiffiffiffiffi
1{s2
p
 
, where T is the liability threshold. The liability
threshold is related to the overall probability of disease in the
population (K), with T~W{1(1{K). While we shall mainly focus
on lifetime risks in this study, K can also be the probability of
disease in a given period of time, say the 5-year or 10-year risk of
disease. It is easy to see that the measurable liability is monotone
increasing with the predicted risk, thus ROC curve constructed
using either criterion will be identical.
To construct the ROC curve, we need to evaluate specificity
and sensitivity at different percentile cut-offs. Test positive can be
defined as having a measured liability higher than a certain
percentile cut-off c. Pr(Disease +ve|test+ve) (or the positive
predictive value) is given by the average risk of people whose
percentiles of measured liability exceeds the given cut-off c:
Pr (Diseasezvejtestzve)~ 1
1{c
ð1
c
1{W
T{zffiffiffiffiffiffiffiffiffiffiffiffi
1{s2
p
  
dp
where z denotes the liability score at a certain percentile from the
distribution of measurable genetic factors. p is a random variable
representing the percentile of the measurable liability. Note that
we need to integrate over all the percentiles above the cut-off c.
z can also be expressed as the inverse normal of p, i.e.
z~sW{1(p). Hence we have
Pr TPð Þ~Pr Diseasezve and testzveð Þ~
Pr Diseasezvejtestzveð Þ.Pr testzveð Þ
~
1
1{c
ð1
c
1{W
T{sW{1(p)ffiffiffiffiffiffiffiffiffiffiffiffi
1{s2
p
  
dp|(1{c)
~
ð1
c
1{W
T{sW{1(p)ffiffiffiffiffiffiffiffiffiffiffiffi
1{s2
p
  
dp
The other cells in the 262 table are computed readily given
Pr(TP). Sensitivity and specificity are calculated using 5000
percentile cut-offs. Area under the curve (AUC) is then estimated
from the graph using the R function integrate.xy from the sfsmisc
package. Note that the positive and negative predictive values of
the test can also be obtained for any arbitrary percentile cut-off.
Approximation of TPR, FPR, and AUC by the binormal
ROC curve
The binormal ROC curve is a classic example in ROC
methodologies. In this model, we assume the test results are
normally distributed in the affected and unaffected individuals. In
our case, the test results are the measurable liability scores. We
have already assumed the measurable liability follows a normal
distribution in the whole population. The distributions of the
Table 1. A 262 classification table.
Disease +ve Disease 2ve Total
Test +ve TP FP 1-percentile (c)
Test 2ve FN TN percentile (12c)
K 12K 1
K, overall probability of disease in the population; TP: True positive; FP, false
positive; FN, false negative; TN, true negative. c, percentile cut-off.
doi:10.1371/journal.pgen.1001230.t001
Author Summary
Recently many genetic variants have been established for
diseases, and the findings have raised hope for risk
prediction based on genomic profiles. However, we need
to have proper statistical measures to assess the usefulness
of such tests. In this study, we developed a statistical
framework which enables us to evaluate many predictive
indices analytically. It is based on the liability threshold
model, which postulates a latent liability that is normally
distributed. Affected individuals are assumed to have a
liability exceeding a certain threshold. We demonstrated
that, given the overall disease probability and variance in
liability explained by the genetic markers, we can compute a
variety of predictive indices. An example is the area under
the receiver operating characteristic (ROC) curve, or AUC,
which is very commonly employed. However, the limitations
of AUC are often ignored, and we proposed complementing
it with other indices. We have therefore also computed
other metrics like the average difference in risks between
cases and non-cases, the ability of reclassification into high-
and low-risk categories, and the proportion of cases
accounted for by a certain percentile of population at the
highest risk. We also derived how to construct graphs
showing the risk distribution in population.
Predictive Power Based on Heritability Explained
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measurable liabilities conditioned on the affection status are also usually
close to normal curves. By the Pearson-Aitken (PA) formula
[11,12], we can estimate the mean and variance of the liability
conditioned on the affection status and derive the AUC.
Mean measurable liabilities in affected and unaffected
individuals. We consider the overall and measurable liability of
an individual, denoted by Lind andMind respectively. Selection for
affected individuals changes the overall liability to a truncated
normal distribution, with mean a~w(T)=½1{W(T) and variance
b~1{a2zaT . We shall use the subscripts A and A to denote
affected and unaffected individuals respectively. Applying the
Pearson-Aitken selection formula, it can be shown that within
affected individuals, the mean of Mind = mA = as
2 and the variance
of Mind = s
2
A = s
2 [12(12b) s2].
Similarly, selection for unaffected individuals changes the
overall liability to a truncated normal distribution (this time the
truncation is from above) with mean c~{w(T)=W(T) and
variance d= 1{c2zcT . Within unaffected subjects, the mean of
Mind =mA = cs
2 and the variance of Mind = s
2
A
=s2[12(12d) s2].
The approximation formulas. The measurable liabilities in
the affected and unaffected groups can be assumed to follow
normal distributions:
Mind,affected*N(mA,s
2
A)
and
Mind,unaffected*N(mA,s
2
A)
The AUC for the binormal ROC curve can be expressed in a
simple form [13] :
AUC~W
(mA{mA)=sAffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
1z(sA=sA)
2
q
0
B@
1
CA
We may assume that the variances of measurable liability in the
affected and unaffected groups are approximately equal, especially
for more common diseases. AUC can then be approximated by
the following formula (see supplementary methods in Text S1):
AUC~W
as2 1z
K
1{K
 
=sAffiffiffi
2
p
0
BB@
1
CCA
where sA is the standard deviation in cases. This method of
estimating AUC does not involve any numerical integration or
simulations and can be easily implemented in a spreadsheet.
Alternatively, to improve the accuracy of AUC estimate, we may
calculate sA=sA using the actual standard deviations of measurable
liability (derived using the PA formula) in affected and unaffected
groups. The formulas have been described previously.
By assuming normality in the measurable liability distributions in
cases and controls, we can also provide simple formulas to approximate
the TPR (i.e. sensitivity) and FPR (i.e. 1-specificity) given a risk
threshold. The idea is to convert the absolute risk to its corresponding
risk percentile within cases or controls. Within cases, we have
R~1{W
T{zffiffiffiffiffiffiffiffiffiffiffiffi
1{s2
p
 
and
z~W{1(p)sAzmA
Substituting the 2nd expression into the 1st and change p to be the
subject of formula,
p~W
T{W{1(1{R)
ffiffiffiffiffiffiffiffiffiffiffiffi
1{s2
p
{mA
sA
 !
Within cases, a proportion of (12p) of them have predicted risks above
the risk threshold R and will be classified as ‘‘high-risk’’. The true
positive rate (TPR) is simply 12p. By the same argument, we can also
compute the approximate false positive rate (FPR) (=1- specificity),
by
FPR~1{W
T{W{1(1{R)
ffiffiffiffiffiffiffiffiffiffiffiffi
1{s2
p
{mA
sA
 !
Distribution of predicted risks given a set of known
susceptibility variants
A major purpose of risk prediction is to stratify individuals into
different risk categories of clinical importance. The ROC curve,
however, does not typically display risk thresholds. As shown by
Pepe et al. [7], although one can locate a point on the ROC curve
corresponding to a given risk threshold, it is impossible to compare
the population performances of different models using a particular
risk criterion. This is because the point corresponding to the same
threshold will be at different horizontal and vertical positions.
Other measures and plots are more useful if clinically relevant risk
thresholds or categories are concerned, such as plots of the
predicted risk distribution in the population.
Risk distribution in the whole population. Suppose we
are going to predict disease risks based on a set of known
susceptibility genes or variants. What will be the distribution of the
predicted risks in the whole population?
The predicted absolute risk of disease R can be represented by
Pr (disease)~1{W
T{sW{1(p)ffiffiffiffiffiffiffiffiffiffiffiffi
1{s2
p
 
ð1Þ
where T is the liability threshold, s2 is the variance explained and
p is the percentile of measurable risk derived from known genetic
factors.
The graph of cumulative density function (cdf) of the predicted
absolute risk can be obtained by plotting the risk percentiles
against the predicted risks. The probability density function (pdf)
[denoted g(R)] is derived by differentiation of the cdf, or dp/dR.
The detailed mathematical derivations and results may be found
in the supplementary methods (Text S1). We also derived formulas
for the risk distribution within cases and controls.
The predictiveness curve. The predictiveness curve, first
proposed by Pepe et al. [7], is a useful way to visualize the
predictive power of a test and the distribution of risk in the
population. This curve is constructed by plotting the predicted
absolute disease risks against the percentiles of the absolute risks,
or transposition of the cdf curve. Since the measurable liability has
a monotonic relationship with the predicted absolute risk (i.e. a
higher measurable liability always leads to a higher risk), the
Predictive Power Based on Heritability Explained
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percentiles of the measurable liability can also be used. The curve
may be produced based on equation (1), which relates the
percentile and the predicted risk. Examples of predictiveness
curves for different levels of variance explained are shown in
Figure 1. This curve is useful for visualizing the proportion of
population exceeding certain risk thresholds. Risk models can also
be compared based on the same risk threshold. For example,
adding susceptibility loci to a prediction model may increase the
proportion of people exceeding the risk threshold. One may also
look for the corresponding threshold given a percentile.
The predictiveness curve contains the same information as the pdf
or cdf plots. The pdf curve is more intuitive, but it is also more difficult
to derive and does not display the percentile and absolute risks directly.
Area under the predictiveness curve and proportion of
cases explained
One way to assess the predictive power is to estimate the
proportion of cases that be accounted for by a given percentage
(e.g. half) of the population at the highest risk. This measure, for
instance, has been used to evaluate the predictive power of genetic
factors for breast cancer [14]. It turns out that the area under the
predictiveness curve is directly related to this measure.
The proportion of cases occurring in the Ptop% of the
population at the highest risk is given by
ð1
1{Ptop=100
1{W
T{sW{1(p)ffiffiffiffiffiffiffiffiffiffiffiffi
1{s2
p
  
dp=K
where K is the average probability of disease in the population. As
an example, we consider the top 20% of the population at the
highest risk in Figure 2. The proportion of cases explained by these
20% of population is equal to the green area divided by the total
area under the predictiveness curve ( =K).
Area under the curve when proportion of cases
explained is plotted against population at the highest
risk
We can plot the proportion of population at the highest risk (or
equivalently the cumulative proportion of population arranged in
descending order of their predicted risk) on the x-axis and the
proportion of cases explained on the y-axis and obtained a curve.
The area under this curve has been proposed as a measure of the
AUC (area under the curve when sensitivity is plotted against 1-
specificity). For example Clayton in a commentary [15] and a
recent study in New England Journal of Medicine [16] consider
the AUC of this plot to be equivalent to the AUC of the more
conventional plot of sensitivity against (1-specificity). This is
however not correct, as will be proved later. In fact, this curve may
also be regarded as an alternative version of the Lorenz curve [17],
originally used for showing wealth distribution. The Lorenz curve
plots the cumulative proportion of population arranged in ascending
order of their predicted risks on the x-axis and the cumulative
proportion of cases on the y-axis. The area above the Lorenz curve
is equivalent to the area under the curve when population at the
highest risk is plotted against the proportion of cases explained.
Note that similar to the ROC curve, the Lorenz curve does not
contain information about the absolute risks.
We derive an analytic form of the conventional (or true) AUC
and compare to the area under this new plot using the variance
explained framework. We show that these two measures are not
equal, but are close when the outcome is rare. Readers please refer
to the supplementary methods (Text S1) for detailed derivations.
Figure 1. Predictiveness curves for different levels of variance explained. The percentile of measurable liability is equivalent to the
percentile of absolute risk. The disease probability in the population is set at 0.1.
doi:10.1371/journal.pgen.1001230.g001
Predictive Power Based on Heritability Explained
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It can be shown that the true AUC is given by
AUC~
ð1
0
sens(c)d(1{spec(c))
~
ð1
0
ð1
c
1{W
T{sW{1(p)ffiffiffiffiffiffiffiffiffiffiffiffi
1{s2
p
  
dp=K

| W
T{sW{1(c)ffiffiffiffiffiffiffiffiffiffiffiffi
1{s2
p
 
=(1{K)
 
dc
where c is the percentile cut-off of the measurable liability.
Now suppose we plot the proportion of population at the
highest risk on the x-axis and the proportion of cases explained on
the y-axis. The area under this curve is
ð1
0
ð1
c2
1{W
T{sW{1(p)ffiffiffiffiffiffiffiffiffiffiffiffi
1{s2
p
  
dp=K
( )
dc2
where c2 is a percentile cut-off point.
This area differs from the previous (true) AUC by a factor of
W
T{sW{1(c)ffiffiffiffiffiffiffiffiffiffiffiffi
1{s2
p
 
=(1{K) in the integrand. When variance
explained (s2) is small and T is large (i.e. the outcome is rare),
the numerator is roughly equal to W(T), or (12K). Thus the two
measures are close when the outcome is rare, but are not identical
mathematically.
Net reclassification improvement (NRI)
For many diseases, there exist a priori risk categories to guide
the plans of management for patients. For instance, the Third
Adult Treatment Panel (ATP III) guideline suggests dividing the
10-year coronary heart disease risks into three categories (0 to 6, 6
to 20 and .20%). In clinical practice, we are often interested in
whether adding a new biomarker or test will improve the re-
classification of subjects into risk categories. The ability to
reclassify subjects has therefore been suggested as a measure to
assess a new biomarker or test [9]. This approach is not only
clinically relevant, but may also be more sensitive than AUC, as
shown in an example of predicting coronary heart disease by
introducing high-density cholesterol to the model [9].
We now connect the variance explained framework to the
notion of net reclassification improvement. Assume there are two
prediction models which share all risk factors, except for a new
biomarker. Our aim is to estimate the improvement in
reclassification when the new marker is added. The performances
of the models are considered separately for those who develop the
event and for those who do not. We cross-tabulate the predicted
absolute risks according to preset risk categories for the two
models. An example of such a re-classification table can be found
in Table 2 of Pencina et al [9].
Let D be the event indicator. We classify downward movement
(down) as a change to a lower risk category under the new model
and upward movement (up) as a change to a higher risk category.
Pencinia et al.[9] defined the net reclassification improvement
(NRI) as
NRI~ P upjD~1ð Þ{P downjD~1ð Þ½ 
{ P upjD~0ð Þ{P downjD~0ð Þ½ 
To evaluate the NRI under a variance explained framework, we
need to consider three liability distributions: (1) the overall liability
(Loverall ), (2) the measurable liability under the old model (Mold ) and
(3) the measurable liability under the new model (Mnew). Note that
Mnew~MoldzMextra, where Mextra is the measurable liability
Figure 2. Area under the predictiveness curve and proportion
of cases explained. The proportion of cases explained by the 20%
population at the highest risk is equal to the green shaded area divided
by the total area under the predictiveness curve.
doi:10.1371/journal.pgen.1001230.g002
Table 2. A typical re-classification table with 3 risk categories.
Old model (without the new biomarker) New model (with the new biomarker)
Predicted Risk ,6% 6–20% .20%
Those who develop the event
,6% a11 a12 a13
6–20% a21 a22 a23
.20% a31 a32 a33
Those free of the event
,6% b11 b12 b13
6–20% b21 b22 b23
.20% b31 b32 b33
doi:10.1371/journal.pgen.1001230.t002
Predictive Power Based on Heritability Explained
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attributed to the new risk factor(s) introduced. We assume the new
risk factor is independent of the existing risk factors, or Mextra is
independent of Mold . This may not be true in some cases, such as
adding genetic markers associated with lipid levels or blood pressure
to a prediction model of coronary artery disease that has already
included these risk factors. The framework presented below can deal
with such complications theoretically, however the covariance
betweenMold andMnew needs to be correctly specified beforehand.
The vector [Loverall , Mold , Mnew] has the following mean and
covariance matrices
m~
0
0
0
2
64
3
75 S~
1 Vold Vnew
Vold Vold Vold
Vnew Vold Vnew
2
64
3
75
where Vold and Vnew are the total variance explained under the old
and new prediction models respectively.
Let us consider the group who develop the event of interest.
Applying PA formula, the mean and variance of the vector
[Mold Dcase, MnewDcase] are as follows:
~m~
0
0
 
z
Vold
Vnew
 
(1)(a{0)~
aVold
aVnew
 
~V~
Vold Vold
Vold Vnew
" #
{
Vold
Vnew
" #
(1{b) Vold Vnew½ 
~
Vold{(1{b)V
2
old Vold{(1{b)VoldVnew
Vold{(1{b)VoldVnew Vnew{(1{b)V
2
new
" #
The mean and variance of Mold and Mnew within the non-cases
are calculated in a similar manner.
Recall that the predicted risk R can be calculated by
R~1{W(
T{zffiffiffiffiffiffiffiffiffiffiffiffi
1{s2
p )
Hence
z~T{½W{1(1{R)
ffiffiffiffiffiffiffiffiffiffiffiffi
1{s2
p	 

Suppose there are 3 preset risk categories: 0 to r1, r1 to r2 and r2 to
1. Note that the method can also be readily extended to deal with
any number of categories. The corresponding quantile of the
measurable liability (z) can readily be obtained from the above
formula, given the variance explained. As an example, among the
cases, the probability of moving from 0 to r1 category under the
old model to the r1 to r2 category under the new model is given by
ðzr1,old
{?
ðzr2,new
zr1,new
w2(Mold Dcase,MnewDcase)dMold DcasedMnewDcase
where zr1,old , zr1,new and zr2,new are the quantiles of the measurable
liability corresponding to the specified risk under the old or new
models. w2 denotes the bivariate normal density function. Since
the mean and covariance matrix of [Mold Dcase, MnewDcase] is known,
the above integral can be readily computed. The probabilities of
other patterns of changes in risk categories can be obtained by
altering the upper and lower limits of the integral.
To illustrate how the NRI is calculated, consider the following
example in which two models are used to predict the risk of an
event and the risk categories are 0–6%, 6–20% and .20% (i.e.
r1 = 0.06 and r2 = 0.2). Table 2 illustrates how the re-classification
table would look like. Note that all table cells are expressed in
probabilities, such that
P
ij
aij~1 and
P
ij
bij~1. For instance,
a12 = (no. of cases who moved from ,6% category to 6–20%
category) / (total no. of cases)
All the cells can be computed analytically by bivariate
integration. For example, the bivariate integral shown above
calculates cell a12. We have
P upD ~1ð Þ~a12za13za23
P downD ~1ð Þ~a21za31za32
P upD ~0ð Þ~b12zb13zb23
P downD ~0ð Þ~b21zb31zb32
Integrated discrimination improvement
The reclassification improvement is dependent on the choice
of risk categories. Pencina et al. [9] suggests an extension of NRI
to overcome this drawback. Instead of setting only a few
categories, now each person represents a separate category. In
this case, it is sensible to consider the actual changes in predicted
probabilities rather than simply the directions of movement
in risk categories. Denoting the predicted disease probabilities
under the old and the new modes be p^old and p^new respectively,
we have the following index known as integrated discrimination
improvement:
ID^I~
P
i in cases
½p^new(i){p^old (i)
No: of cases
{
P
j in non-cases
½p^new(j){p^old (j)
No: of non-cases
Pencina et al. showed that the above index has another intuitive
meaning: it is equal to the difference in Yate’s discrimination
slopes (DS) [18] under the two models. The discrimination slope
is equal to the difference in mean predicted risks in cases and
non-cases. Therefore we have
ID^I~(^pnew,cases{
^pnew,non{cases){(
^pold,cases{
^pold,non{cases)
Since we have derived the pdf of predicted risks in case and non-
cases previously, the discrimination slope can be deduced for any
model and IDI can be calculated easily for two nested models.
Let gcase(R) and gnoncase(R) be the pdf of predicted risks in cases
and non-cases respectively, the discrimination slope under a
certain model is simply
DS~
ð1
0
Rgcase(R)dr{
ð1
0
Rgnoncase(R)dR
Predictive Power Based on Heritability Explained
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Standard deviation of the predicted risks
The variance or standard deviation (SD) of the risk distribution
is another index to the predictive ability of a test. A test which high
discriminatory power should assign more dispersed risk estimates
to subjects. In contrast, subjects’ risk estimates tend to be close for
a test that discriminates poorly.
If g(R) is the pdf of the risk distribution, the variance of the risk
distribution is
var(R)~
ð1
0
(R{K)2g(R)dR
where K mean disease risk in the population. It is also useful to
compare var(R) with the maximum variance that can be achieved.
In the perfect case, all cases are assigned a risk of 1 and all non-
cases are assigned a risk of 0. The variance of risk under this
perfect scenario is given by the variance of a Bernoulli variable i.e.
K(12K). The ratio of the observed variance to the maximum
achievable variance is hence
Ð 1
0
(R{K)2g(R)dR
K(1{K)
Interestingly, this ratio is equal to the mean risk difference between
cases and controls, or the discrimination slope, as shown in Pepe et
al [19]. The results in Table 3 confirmed this relationship.
Simulations
We performed a simulation study to check our results. We
simulated a hypothetical cohort study of 1 million people. The
‘‘true’’ predicted risk of disease is based on a logistic model,
log
P
1{P
 
~b0zb1x1zb2x2:::zbnxn
and
P~
exp (b0zb1x1zb2x2:::zbnxn)
1z exp (b0zb1x1zb2x2:::zbnxn)
where P is the true predicted risk of disease. The outcomes of
individuals were simulated from P. The outcome was set to 1 if a
randomly generated uniform variable was less than the true
predicted risk and vice versa. To ensure that the allele frequencies
and effect sizes in our simulations are realistic, we extracted the
allele frequencies and odds ratios from a list of 30 known
susceptibility variants for prostate cancer. The data were based on
the National Human Genome Research Institute (NHGRI)
catalog. The loci were assumed to be independent and genotypes
(coded 0, 1 and 2) were simulated randomly from the allele
frequencies. The model was additive on the log-odds scale, or
equivalently multiplicative on the odds ratios scale. The regression
coefficients b1…bn were derived from log(OR) and b0 was
adjusted to yield disease probabilities that were approximately
equal to 0.005, 0.01 and 0.1. The precise disease probability is not
important as our aim is just to compare theoretical and simulation
results. We computed predictive metrics and constructed histo-
grams of predicted risks and predictiveness curves based on the
simulated disease status and predicted risks. The calculations were
repeated using the allele frequencies and effect sizes of the first 10,
20 and 30 variants from Table S1. The somers2 function in the
Hmisc package was used to compute the AUC.
To compute the NRI in simulations, the outcomes and true
predicted risk were first simulated with the above method using all
30 loci. Then we fitted a logistic regression model using only the
first 20 loci, treating it as the old model. The NRI from the old
model (20 loci) to the new model (30 loci) was computed.
As a more technical consideration, the OR is not exactly equal
to the risk ratio which is required for calculating the variance
explained. Zhang and Yu [20] have proposed a simple correction
of OR to the risk ratio in cohort studies. We modified their
approach to accommodate the three genotypes (or ‘‘exposures’’) in
our case (So et al. submitted [10]). The resulting risk ratio
estimates were used as inputs.
Results
Predictive indices obtained by analytic calculations and simula-
tions are presented in Table S2. The results from both approaches
were very close in all scenarios. Figure 3 and Figure 4 show
comparisons of the predictiveness curves and the risk distributions
from simulations and our theoretical calculations. Again the graphs
derived from analytic means match very well with the simulation
results. The results confirm our derivations and show that a
multiplicative model on the OR scale is very similar to an additive
model on the liability scale. This is equivalent to the similarity
between probit and logit models in generalized linear modeling
[21]. Also of note is that the AUCs from the approximation
formulas are close to the more accurate version. In addition, the
AUCs are almost identical given an identical set of susceptibility
SNPs, regardless of disease prevalence. This is because AUC only
depends on the ranks of predicted risks but not actual risk levels.
Table S3 shows the NRI and its components (probability of moving
up or down categories in cases and non-cases) from theoretical
derivations and simulations. They are reasonably close, though the
discrepancy is slightly larger than in the previous table. The
discrepancy may be due to difference in model assumptions (probit
Vs logit) and slight sampling variability. As NRI involves the risks
estimates from two models and their covariance, any difference in
model assumptions may be exaggerated. NRI also involves the
discretization of risks into categories in two models, and this may
also lead to a slightly higher discrepancy.
We created some combinations of disease probability (K) and
variance explained and computed the predictive metrics in each
case (Table 3). As expected, all the prediction metrics improve
when Vm increases. This includes increases in AUC, proportion of
cases explained by people at highest risk, variance of the predicted
risk, the mean risk difference and the range and relative risk at the
10th and 90th percentiles.
We now considered how the predictive metrics changes at different
prevalences, given a fixed level of Vm. As shown in Table 3, the AUC
and the proportion of cases explained decreases with increasing
prevalence. The mean risk difference in cases and controls is wider
when the disease is more common, given the same Vm. The relative
risk by comparing the risks at 10th and 90th percentiles is larger at
lower prevalences, but the range is larger at higher prevalences.
Next some combinations of Vm under the old and new
prediction models are considered (Table 4). The risk thresholds
were set at 6% and 20% under overall prevalences of 5% and
10%. Under the simulated scenarios, we observed that the
magnitude of NRI is the largest, followed by the increase in
AUC, and the IDI is the smallest. It is noteworthy that it is possible
the AUC increase is unimpressive but the NRI is more substantial.
For example when the variance explained increases from 20 to
25% at K=0.05 or 0.1, the AUC increases by only about 0.03
while the NRI is around 11%.
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Finally we applied our methodologies to a number of complex
diseases to evaluate the predictive performance achievable by the
known susceptibility loci (Table 5). To our knowledge, this is by far
the most comprehensive assessment of predictive power based on
established susceptibility variants, in terms of both the number of
diseases and the variety of predictive metrics covered. We
computed the total variance explained by established susceptibility
variants for each disease. Details of the survey are provided
elsewhere (So et al., submitted [10]).
As shown in Table 5, the AUC for the diseases are in general
not very high, but the AUC for type 1 diabetes and systemic lupus
erythematosus (SLE) reach around 0.75, a threshold that may be
considered clinically useful in discrimination [22]. (Also note that
the MHC variants were not included for type 1 diabetes.) The
mean risk differences in affected and unaffected individuals range
from almost 0 to about 7%, the difference being larger for more
common diseases. The relative risk and the range between the
10th and 90th percentiles were also shown. The largest relative
risk was about 14 times (type 1 diabetes) and the widest range was
around 30% (type 2 diabetes). We note that this sort of comparison
may be quite arbitrary as one can compare any 2 percentile cut-
offs. We merely aim at providing an idea of how dispersed the risks
are at different percentiles. For a more comprehensive assessment,
one can look at the predictiveness curve and use formulas derived
before for the predicted risk at any percentile. Figure 5 contains a
panel of six graphs showing the predictive performance of known
variants for breast cancer. Similar graphs for the other diseases
studied are shown in Figures S1, S2, S3, S4, S5, S6, S7, S8.
Discussion
We have shown in this study that the variance explained
framework enables us to evaluate the predictive or discriminatory
power of tests analytically. Under this framework, the overall
probability of disease and the total variance explained are the two
fundamental quantities that determine the distribution of predict-
ed risks and the predictive power. Note that we mainly considered
lifetime risk in the current study, although one can also consider
the probability of disease in a specified period of time. The
distribution of predicted risks in the population can be derived
analytically given the overall probability of disease and the
variance explained. We can also compute many indices of
predictive power, such as AUC, discrimination slope, reclassifica-
tion improvement and the proportion of cases explained by
specific percentile of population at the highest risk. Hence the
concept of variance explained provides a unifying framework that
connects different approaches to prediction model assessment.
Although the methods presented are primarily motivated and
demonstrated using genetic markers, they can also be applied to
other biomarkers or environmental risk factors.
The methodology described here can be applied to case-control
studies, as long as the overall probability of outcome and variance
explained are known. By supplying the overall disease probability,
the appropriate absolute risks and reclassification indices can be
computed. This is verified by our simulation which is equivalent to
a cohort study. Using the variance explained derived from allele
frequencies and ORs, all the prediction metrics and plots from our
theoretical calculations approximates the simulation results very
well. Another advantage of risk prediction based on the variance
explained framework is that it can be extended to deal with
markers in LD, haplotypes or multilocus genotypes. These
extensions will be discussed elsewhere (So et al., submitted [10]).
A note on the optimality of the ROC curve
Recently Lu and Elston [4] have suggested a way to construct
the optimal ROC curve, based on likelihood ratios. An optimal
ROC curve is one that maximizes the true positive rate for any
Table 3. Predictive indices under different combinations of overall disease probability (K) and variance explained (s2).
K=0.005 K=0.005 K=0.005 K=0.01 K=0.01 K=0.01 K=0.05 K=0.05 K=0.05 K=0.1 K=0.1 K=0.1
s2 =0.05 s2 =0.1 s2 =0.2 s2 =0.05 s2 =0.1 s2 =0.2 s2 =0.05 s2 =0.1 s2 =0.2 s2 =0.05 s2 =0.1 s2 =0.2
AUC accurate 0.678 0.746 0.832 0.666 0.730 0.814 0.635 0.690 0.765 0.622 0.672 0.742
AUC approx 0.677 0.742 0.821 0.665 0.726 0.803 0.634 0.686 0.754 0.621 0.669 0.731
AUC approx2 0.679 0.747 0.833 0.667 0.731 0.815 0.636 0.691 0.766 0.623 0.673 0.744
Prop cases exp 0.1 0.258 0.350 0.505 0.241 0.323 0.460 0.201 0.255 0.346 0.182 0.224 0.293
Prop cases exp 0.2 0.421 0.530 0.691 0.401 0.500 0.650 0.349 0.421 0.535 0.323 0.382 0.474
Prop cases exp 0.5 0.746 0.831 0.924 0.729 0.812 0.906 0.681 0.752 0.845 0.656 0.719 0.805
Var of risk 1.23E-05 2.90E-05 7.97E-05 4.06E-05 9.27E-05 2.39E-04 5.68E-04 1.21E-03 2.75E-03 1.60E-03 3.34E-03 7.20E-03
Var of risk to max 0.0025 0.0058 0.0160 0.0041 0.0094 0.0241 0.0120 0.0255 0.0578 0.0178 0.0371 0.0800
Mean risk in cases 0.0075 0.0108 0.0209 0.0141 0.0193 0.0339 0.0614 0.0743 0.1049 0.1160 0.1334 0.1720
Mean risk in noncases 0.0050 0.0050 0.0049 0.0100 0.0099 0.0098 0.0494 0.0487 0.0472 0.0982 0.0963 0.0921
Mean Risk Diff 0.0025 0.0058 0.0160 0.0041 0.0094 0.0241 0.0120 0.0255 0.0577 0.0178 0.0371 0.0799
Risk at 10th percentile 0.0017 0.0008 0.0002 0.0037 0.0020 0.0006 0.0238 0.0153 0.0066 0.0538 0.0377 0.0191
Risk at 90th percentile 0.0094 0.0111 0.0126 0.0182 0.0214 0.0250 0.0817 0.0957 0.1154 0.1537 0.1778 0.2142
RR from 10th to 90th 5.68 13.21 58.42 4.95 10.76 42.06 3.44 6.23 17.56 2.85 4.72 11.24
Range from 10th
to 90th
0.0078 0.0102 0.0124 0.0145 0.0194 0.0244 0.0580 0.0803 0.1088 0.0998 0.1401 0.1951
AUC accurate, accurate AUC obtained by the integration formula as described in text; AUC approx, AUC approximated by binormal curve and assuming equal variance
in cases and controls; AUC approx2, AUC approximated by binormal curve and unequal variance in cases and controls.
Prop cases exp 0.1, proportion of cases explained by the people at top 10% of risk; similar abbreviations used for the next 2 items.
Var : variance ; max, maximum ; Diff, difference; RR, relative risk.
doi:10.1371/journal.pgen.1001230.t003
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fixed value of false positive rate and hence gives the maximum
AUC. Another method to construct the optimal ROC curve is
simply to use the risk score function or the predicted probability of
disease, Pr(disease| test result). This method is perhaps less
recognized and has not been mentioned in Lu and Elston [4]. It
has been shown that the risk score is a monotone increasing
function of likelihood ratios, and therefore also gives the optimal
ROC curve [23]. In our methodology, construction of the ROC
curves (and AUC) are all based on the actual predicted risks, or
equivalently the liability score, which is a monotone increasing
function of the actual risks. As a result, the ROC curve produced
by our method should be optimal by definition. In practice, the
‘‘optimality’’ will depend on whether the risks are specified
correctly by the most appropriate model. Our approach is to
assume an underlying normal liability distribution. Another
common approach is to assume a logistic model, which is the
same as assuming ORs are multiplicative. These 2 models (normal
Vs logistic) are however very close, and in reality it is difficult to tell
which one is closer to the truth.
On measures of predictive power and the limitations of
AUC
Broadly speaking, individualized estimates of disease risk serves
two main purposes. One is accurate classification of individuals
into two distinct groups, diseased or not diseased. Such high levels
of accuracy in classification are required, for example in disease
diagnosis or identifying subgroups of people for costly and/or
invasive screening procedures or interventions. The actual disease
risks are relatively unimportant. In this case AUC is an
appropriate measure of predictive ability.
Another purpose is to better stratify people into risk categories
and offer different management or screening strategies according
to the level of predicted risks. The intervention or screening plans
are typically less expensive or risky. For example, subjects having a
10-year risk of breast cancer over a certain percentage may be
recommended for mammography screening. In that case, the
increase in AUC by adding genetic markers to the prediction
model may not be the primary concern. Instead, it is more
pertinent to know how well an individual may be reclassified into
the ‘‘screening’’ and ‘‘no screening’’ groups. This idea of using the
reclassification concept to assess a predictive model has been
discussed in previous studies [6,9].
AUC has been widely used to measure the ability of risk
prediction for sets of genetic variants and other biomarkers. As
Figure 3. Comparison of the predictiveness curves from
simulated data and theoretical calculations. The predictiveness
curve plots the predicted risk against risk precentiles. The overall
disease risk K= 0.005 and 30 loci from Table S1 were included. The black
dotted line represents results from simulations and the green solid line
is obtained by theoretical calculations. The total variance explained is
equal to 0.0442. The theoretical estimates of predicted risks are from
equation (1), i.e. Pr (disease)~1{W
T{sW{1(p)ffiffiffiffiffiffiffiffiffiffiffiffi
1{s2
p
 
, where T is the
liability threshold, s2 is the variance explained and p is the percentile of
measurable risk derived from known genetic factors.
doi:10.1371/journal.pgen.1001230.g003
Figure 4. Comparison of predicted risk distributions from
simulated data and theoretical calculations. The overall disease
risk K=0.005 and 30 loci from Table S1 were included. The histogram
was obtained from simulations data, while the blue line showing
probability density was derived from theoretical calculations. The
theoretical distribution was obtained by differentiating the cumulative
density function of estimated risks.
doi:10.1371/journal.pgen.1001230.g004
Table 4. Improvement in predictive indices with increase in
variance explained.
K Vold Vnew NRI AUC increase IDI
0.05 0.05 0.1 0.099 0.055 0.014
0.05 0.15 0.195 0.096 0.029
0.1 0.15 0.102 0.041 0.015
0.1 0.2 0.202 0.075 0.032
0.2 0.25 0.104 0.029 0.019
0.2 0.3 0.201 0.054 0.040
0.1 0.05 0.1 0.166 0.050 0.019
0.05 0.15 0.306 0.089 0.040
0.1 0.15 0.142 0.038 0.021
0.1 0.2 0.262 0.070 0.043
0.2 0.25 0.109 0.028 0.024
0.2 0.3 0.205 0.053 0.049
Vold and Vnew refers to the variance explained under the old and new models
respectively.
doi:10.1371/journal.pgen.1001230.t004
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mentioned previously, there are limitations in just using AUC to
quantify the predictive power of a test. More detailed discussions
on the shortcomings are presented elsewhere [6,7,24]. In brief,
AUC is not a function of the actual predicted risks. As an extreme
example described by Cook (2007), a risk model that assigns a risk
of 0.52 to all cases and 0.51 to all non-cases achieved perfect
discrimination but is not clinically useful. The benefit of new
markers in reclassification cannot be captured by AUC as it
contains no information about the predicted risks. AUC only
depends on the rank of the test results (or the model risks) and
ignore the magnitude of differences. If all the predicted risks are
multiplied by a factor of 10, the ranks and hence the ROC curve
or AUC will stay unchanged, but the clinical impact is very
different [24].
Another criticism concerns the interpretation of AUC. AUC
equals the probability that the risk of a case is higher than a non-
case. This is however not directly clinically relevant since
physicians do not see patients in pairs and it is not necessary to
decide which person in a pair will develop the disease.
Moreover, the ROC curve and AUC considers all possible
cutoffs for the test results or model risks and the specificity and
sensitivity at each cutoff. As a result, no pre-specified cutoff is
required. However, if there exist established risk thresholds, then a
large part of the ROC curve will in fact be derived from cutoff
points not of clinical interest.
We reckon that a more comprehensive assessment of prediction
model performance may be achieved by complementing AUC
with other available prediction indices and graphs, such as NRI,
IDI and risk distribution plots, particularly when there exist
meaningful risk thresholds. If there are no such thresholds, NRI
may not be useful, but AUC, IDI and distribution of risks in the
population can still be evaluated. The practical choice or emphasis
on which metric is dependent on the clinical context.
Areas not addressed
Several areas have not been addressed in this study. We have
not considered model calibration, which is a measure of how close
the predicted probabilities of outcome match the actual probabil-
ities. Calibration may be assessed by dividing subjects into deciles
of risk and compare the mean predicted risk with the actual
proportion of outcomes in each decile. The goodness of fit may be
tested by a chi-square test, also known as the Hosmer-Lemeshow
test [25]. The predictiveness curve can also be used to visualize the
goodness-of-fit [7]. We have assumed perfect calibration when
deriving the results. Interaction between SNPs, for example, may
affect calibration. Exploration of interactions will be a useful next
step after the single-SNP analyses in GWAS.
The measured liability is assumed to be normally distributed. If
we consider a number of SNPs with small effect sizes (as is the case
in many complex diseases), the normal assumption is usually
acceptable. However, if a disease has one or a few variants with
particularly large effects, the normal assumption may not hold. For
example, consider a disease with a biallelic locus showing large
effects and ten other SNPs with modest effects. The resulting
measured liability can be regarded as a mixture of three normal
distributions. The mixing proportion will depends on the genotype
frequencies of the large-effect locus. The analytic computation of
predictive indices will be much more complex. Simulations may
need to be performed to assess the predictive power of genetic
variants in complicated cases. As an example, for Alzheimer’s
disease the APOE locus exerts a large effect compared to other loci
[26], hence the normal assumption is more dubious and analytic
calculations of predictive metrics may not be very accurate.
Another potential problem is that the effect size measures may
not be accurate. For example, the effect size of the top significant
results in a GWAS may be subject to the ‘‘winner’s curse’’, leading
to overestimation of OR. Methods to correct for this bias were
Table 5. Predictive indices for nine complex diseases.
Bipolar Ca Breast CAD Crohn Ca Prostate SCZ SLE DM1 DM2
Lifetime Risk 0.021 0.127 0.3365 0.0060 0.156 0.0072 0.0031 0.0066 0.2895
Vm 0.0214 0.057 0.123 0.074 0.125 0.003 0.087 0.109 0.118
No. of variants 5 13 12 32 27 4 23 45 25
AUC accurate 0.600 0.625 0.662 0.711 0.680 0.543 0.741 0.750 0.661
AUC approx 0.600 0.624 0.658 0.708 0.675 0.544 0.738 0.745 0.657
AUC approx2 0.601 0.626 0.664 0.712 0.681 0.544 0.742 0.751 0.663
Prop cases exp 0.1 0.174 0.181 0.173 0.298 0.218 0.130 0.345 0.353 0.180
Prop cases exp 0.2 0.310 0.322 0.314 0.471 0.376 0.246 0.523 0.535 0.324
Prop cases exp 0.5 0.639 0.656 0.655 0.788 0.716 0.562 0.825 0.835 0.664
Var of risk 5.68E-05 2.56E-03 1.66E-02 2.66E-05 7.62E-03 1.28E-06 1.05E-05 5.24E-05 1.41E-02
Var of risk to max 0.0028 0.0231 0.0745 0.0045 0.0578 0.0002 0.0034 0.0079 0.0687
Mean risk in cases 0.0237 0.1472 0.3859 0.0104 0.2048 0.0074 0.0065 0.0145 0.3383
Mean risk in noncases 0.0209 0.1241 0.3114 0.0059 0.1470 0.0072 0.0031 0.0066 0.2696
Mean Risk Diff 0.0028 0.0231 0.0745 0.0045 0.0578 0.0002 0.0034 0.0079 0.0687
Risk at 10th percentile 0.0124 0.0682 0.1759 0.0015 0.0588 0.0058 0.0005 0.0011 0.1444
Risk at 90th percentile 0.0310 0.1950 0.5119 0.0122 0.2754 0.0087 0.0067 0.0148 0.4517
RR from 10th to 90th 2.50 2.86 2.91 8.32 4.69 1.49 12.23 13.92 3.13
Range from 10th to 90th 0.019 0.127 0.336 0.011 0.217 0.003 0.006 0.014 0.307
Vm , level of variance explained. Bipolar, bipolar disorder; Ca Breast, breast cancer; CAD, coronary artery disease; Crohn, Crohn’s disease; Ca Prostate, prostate cancer;
SCZ, schizophrenia; SLE, systemic lupus erythematosus; DM1, type 1 diabetes mellitus; DM2, type 2 diabetes mellitus.
doi:10.1371/journal.pgen.1001230.t005
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Figure 5. Graphs showing risk distribution and predictive power of known susceptibility variants for breast cancer. A: ROC curve ; B:
predictiveness curve (predicted risk against risk perecentile) ; C: Cumulative density function of predicted risks ; D: Probability density function of
predicted risks ; E: Probability density function of predicted risks in the population (blue solid line) and in cases (green dotted line) ; F: Proportion of
cases explained against proportion of population at highest risk. While the plots A and F appear similar, they are not identical as shown
mathematically in the text. Similar graphs for other diseases are presented in Figures S1, S2, S3, S4, S5, S6, S7, S8.
doi:10.1371/journal.pgen.1001230.g005
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described elsewhere [27,28,29]. In addition, sometimes cases and
controls may not be representative of the general population. For
example, some studies may recruit cases enriched for family
history or more extreme phenotypes. For the applications in the
current study, the effect sizes are based on combining the initial
GWAS and replication samples, and the bias should in general be
small. As for the practical value of a single GWAS in genetic risk
prediction, Wray et al. [30] used simulated case-control datasets to
consider the predictive performance of selected markers.
As described before, an important aim of risk prediction models
is to stratify people into appropriate risk categories so they may be
subject to different interventions or screening strategies. We have
not discussed issues regarding the determination of risk thresholds.
We need to evaluate the associated costs and benefits before
making such a choice. More mathematical treatment based on a
decision theory framework may be found for example in [31]. In
addition, the costs and benefits may vary with age or other
environmental factors and may vary in different populations. In
practice, medical decision making will need to involve the patient’s
own values and tolerance for risks as well. A recent study by Gail
[32] provided an example on how different metrics based on
public health considerations may be used to assess the perfor-
mance of a breast cancer prediction model with genetic markers.
We have used NRI to assess how a new test will improve the re-
classification of subjects into risk categories. The NRI may also be
viewed as the difference in expected loss between the new test and
the old. Recalling the formula for NRI,
NRI~ P upjD~1ð Þ{P downjD~1ð Þ½ 
{ P upjD~0ð Þ{P downjD~0ð Þ½ 
in fact all the four components are given equal weighting. For
example, the loss incurred by putting a diseased individual in a
lower risk category is assumed to be identical to the loss incurred
by putting a healthy person in a higher risk category. In practice,
this may not be the most appropriate. For instance, we may
consider that putting an affected person into a lower risk category
and hence not giving him/her treatment [the component
P(down|D=1)] is worse than erroneously moving up the risk
category of a healthy individual [the component P(up|D=0)] and
treating the person. This may be true if the morbidity or mortality
of the disease is much greater than the side-effects from treatment.
To tackle this problem one can for example incorporate different
loss functions for the components. This may be done within our
framework by weighing the four components differently. In a
similar vein, Gail [32] considered different loss functions for TP,
TN, FP and FN and evaluated the expected loss for mammog-
raphy screening if the risk threshold was set at a certain optimal
level. As described previously, we can derive all four components
in a 262 classification table (Table 1) and the expected loss can
also be obtained readily by assigning appropriate losses to each
component.
Another noteworthy limitation is that if there exists more than
one risk bin, NRI does not consider the number of risk categories
changed upon adding the new marker. For example, say there are
three risk categories, placing a case in the lowest risk bin and the
second-lowest bin will have the same effect on NRI. To correct
this problem, we may consider giving numeric scores that reflect
the number of categories shifted, as suggested in [28]. For
example, moving up a person who develops the event from
category 1 (lowest risk) to category 3 (highest risk) will receive a
higher score than just moving up to category 2 (intermediate risk).
Again, our framework can be readily extended to deal with this
problem, as we can calculate the probability of changing from any
one risk category to another using bivariate integration.
We have mainly considered lifetime risk when calculating
predictive indices. In clinical practice the risk in a given period of
time may be more relevant than the lifetime risk. For example, the
ATP III guideline quoted above relies on 10-year risk of coronary
heart disease. The use of tamoxifen for breast cancer prevention is
dependent on the 5-year risk of disease [33,34]. It is also worth
noting that the absolute risk of disease is reduced by the chance
that an individual dies of other causes prior to developing the
disease. Our statistical framework can be extended to deal with
risks in a specified period of time (for individuals of a certain age).
In that case, the inputs should be carefully specified. The disease
probability and the relative risks in the specified period of time should
be provided to compute the correct variance explained. The rest of
the calculations remain unchanged. Concepts of absolute risk
estimation were discussed for example in [35]. We describe in a
separate paper [36] the detailed methodologies to derive age-
conditional risk estimates given a follow-up period, accounting for
competing risks in the context of genetic association studies.
We have not considered the variability of the predictive metrics
in this study. It should be noted that the disease probability and
the variance explained by known variants are both subject to
variations, and so will be the predictive metrics derived from these
two quantities. One should be careful in interpretation of the
results if the disease probability or effect sizes of variants are
estimated from small sample sizes.
We noticed a recent study on AUC estimation in the context of
genetic risk prediction [37]. Their study is also based on a liability
threshold model, and they have derived an analytic formula to
approximate the maximum AUC achieved when all genetic loci
are found (at heritability or at fractions of it). Their formula
described is similar to ours under the section on approximation of
AUC by the binormal ROC curve. However, apart from this,
other methodologies presented here have not been described
before. Besides the approximation formula based on normal
distributions in cases and controls, we also provide the exact
formula for AUC as well as formulas to derive all 4 cells in the 262
classification table (given any threshold). Hence we are able to
draw the ROC curve based on analytic methods. Also, not only
are we able to derive the AUC when all heritability has been
explained, but we may also calculate the AUC directly given the
allele frequencies and effect sizes of a set of known susceptibility
loci. We have also argued for other measures and graphs to
evaluate the predictive performance of models and provide
analytic formulas to obtain all relevant indices or plots.
Evaluation of a risk prediction model is no simple task, and
inevitably we cannot perfectly deal with every complexity
involved. Nevertheless, we hope the current study will stimulate
more thoughts on the proper assessment of prediction models and
provide a convenient and useful methodology for researchers to
assess the predictive ability of sets of susceptibility loci. Programs
(written in R) to implement the methodology presented in this
paper are available at https://sites.google.com/site/hon-
cheongso/software/pred-metrics.
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